- ICH GCP
- Registro de ensayos clínicos de la UE
Últimos ensayos
EudraCT Number: 2021-002818-13 | Sponsor Protocol Number: DEALSZ-2021-001 | Start Date: 2023-05-12 | |||||||||||
Sponsor Name: Charité-Universitätsmedizin Berlin | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit... | |||||||||||||
Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003398-79 | Sponsor Protocol Number: MH21HEM | Start Date: 2023-05-11 | ||||||
Sponsor Name: Princess Máxima Center for pediatric oncology | ||||||||
Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C... | ||||||||
Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal... | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: NL (Trial now transitioned) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006456-14 | Sponsor Protocol Number: K321301 | Start Date: 2023-05-10 | |||||||||||
Sponsor Name: Kowa Research Institute, Inc. | |||||||||||||
Full Title: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety ... | |||||||||||||
Medical condition: In Fuchs endothelial corneal dystrophy (FECD), there is an increased rate of loss of endothelial cells, starting in the centre of Descemet’s membrane and spreading to the periphery, resulting in ex... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) DK (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005245-32 | Sponsor Protocol Number: CF102-212LD | Start Date: 2023-05-09 | |||||||||||
Sponsor Name: CanFite BioPharma Ltd. | |||||||||||||
Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003526-50 | Sponsor Protocol Number: HACOL-ACS | Start Date: 2023-05-09 | ||||||||||||||||
Sponsor Name: Hannover Medical School | ||||||||||||||||||
Full Title: A prospective, interventional, single-center, single-arm study to assess the effectiveness of Bempedoic acid to achieve LDL-cholesterol targets in patients following ST-elevation or Non-ST-elevatio... | ||||||||||||||||||
Medical condition: Patients following acute percutaneous coronary intervention for STEMI or NSTEMI insufficiently treated with high-intensity oral lipid lowering therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001771-14 | Sponsor Protocol Number: SRK-015-004 | Start Date: 2023-05-08 | |||||||||||
Sponsor Name: Scholar Rock, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigat... | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) BE (Ongoing) DE (Ongoing) FR (Trial now transitioned) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003289-18 | Sponsor Protocol Number: 219369 | Start Date: 2023-05-08 | ||||||||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer | ||||||||||||||||||
Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Ongoing) NL (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002470-86 | Sponsor Protocol Number: 20190218 | Start Date: 2023-05-08 | ||||||||||||||||
Sponsor Name: Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without... | ||||||||||||||||||
Medical condition: Overweight and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003564-24 | Sponsor Protocol Number: JAB-3312-1003 | Start Date: 2023-05-05 | |||||||||||
Sponsor Name: Jacobio Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P... | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002650-48 | Sponsor Protocol Number: UCDCRC/22/02 | Start Date: 2023-05-05 | |||||||||||
Sponsor Name: University College Dublin | |||||||||||||
Full Title: The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study) | |||||||||||||
Medical condition: pre-heart failure with preserved ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |